Phase 5 · Growth-hormone axis

CJC-1295 and Ipamorelin vs Tesamorelin

CJC-1295 plus ipamorelin is an unapproved two-peptide combination with no established clinical-outcome trial for the blend, whereas tesamorelin is a prescription GHRH analog FDA-approved only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.

The short answer

Different does not automatically mean better.

Side ACJC-1295 + ipamorelin

Side BTesamorelin

Side-by-side

What actually separates them

Compare

CJC-1295 + ipamorelin

Tesamorelin

Identity

CJC-1295 + ipamorelinA combination of a CJC-related GHRH analog and a ghrelin-receptor secretagogue.

TesamorelinA synthetic GHRH(1-44) analog.

Mechanism

CJC-1295 + ipamorelinTwo upstream signals may prompt GH release through different receptors.

TesamorelinPrompts GH release through the GHRH receptor.

Evidence

CJC-1295 + ipamorelinIngredient-level early pharmacology data; no controlled clinical-outcome evidence for a marketed blend.

TesamorelinRandomized trials measured reduced visceral fat in people with HIV and abdominal fat accumulation.

U.S. status

CJC-1295 + ipamorelinNo FDA-approved combination or ingredient drug product for this use.

TesamorelinEgrifta SV is FDA-approved for a narrow HIV-lipodystrophy indication; it is not approved for general weight loss.

Main studied context

CJC-1295 + ipamorelinHealthy-volunteer GH biomarker studies, separately by ingredient.

TesamorelinAdults with HIV-associated lipodystrophy and excess abdominal fat.

Key limitation

CJC-1295 + ipamorelin“Synergy” is a mechanistic claim without a validated blend, outcome trial, or long-term safety profile.

TesamorelinThe registration evidence should not be generalized to people without HIV lipodystrophy or to a CJC/ipamorelin blend.

Evidence check

Known, unknown, and easy to misread

What the evidence shows

CJC-1295 with DAC can raise GH and IGF-1 in small healthy-adult studies; ipamorelin can trigger short GH release in IV pharmacology work.

What it does not prove

In a placebo-controlled HIV study, tesamorelin reduced visceral adipose tissue; its FDA label confines the indication to excess abdominal fat in HIV-infected adults with lipodystrophy.

How to read it

A rise in GH or IGF-1 does not establish comparable fat, fitness, or health outcomes across these therapies.

Beginner bottom line

Quick questions

Frequently asked questions

Is tesamorelin approved for general weight loss?

No; the FDA-labeled indication is specific to HIV-associated lipodystrophy.

Has CJC plus ipamorelin been shown superior to tesamorelin?

No controlled human comparison establishes this.

Do all three increase GH?

They can act upstream of GH release, but the molecules, exposure, studied populations, and evidence are different.

Check the evidence

Primary and official sources

Want to examine the evidence with the community?

Bring a study, ask a focused question, or compare interpretations in Research Discussions.

Visit Research Discussions